As of 2025-05-22, the Intrinsic Value of Ascletis Pharma Inc (1672.HK) is (2.70) HKD. This 1672.HK valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 7.00 HKD, the upside of Ascletis Pharma Inc is -138.60%.
The range of the Intrinsic Value is (5.23) - (1.70) HKD
Based on its market price of 7.00 HKD and our intrinsic valuation, Ascletis Pharma Inc (1672.HK) is overvalued by 138.60%.
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (5.23) - (1.70) | (2.70) | -138.6% |
| DCF (Growth 10y) | (1.72) - (4.74) | (2.59) | -137.0% |
| DCF (EBITDA 5y) | (4.58) - (6.48) | (1,337.33) | -123450.0% |
| DCF (EBITDA 10y) | (3.60) - (5.68) | (1,337.33) | -123450.0% |
| Fair Value | -1.69 - -1.69 | -1.69 | -124.16% |
| P/E | (8.42) - (8.41) | (8.66) | -223.7% |
| EV/EBITDA | (7.81) - (4.02) | (5.78) | -182.5% |
| EPV | (1.59) - (2.57) | (2.08) | -129.7% |
| DDM - Stable | (2.73) - (8.89) | (5.81) | -183.0% |
| DDM - Multi | (2.12) - (5.56) | (3.10) | -144.2% |
| Market Cap (mil) | 6,745.55 |
| Beta | 1.10 |
| Outstanding shares (mil) | 963.65 |
| Enterprise Value (mil) | 5,817.49 |
| Market risk premium | 5.98% |
| Cost of Equity | 10.05% |
| Cost of Debt | 5.64% |
| WACC | 10.04% |